A positive result of double-therapy of both IL-1 and IL-6 blockade, or even triple therapy with dexamethasone in 61% of the patients, was observed in a small case series of 31 hospitalized patient with moderate to severe COVID-19 were 81% was discharged46, but it has not yet been established in a randomized clinical trial whether simultaneous treatment with both IL-1 and IL-6 blockade might have an advantage over therapy with either one of these compounds. Here, IL6 is linked to COVID-19.